Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab ‐paclitaxel for non‐squamous non‐small cell lung cancer with malignant pleural effusion
Conclusion The combination of Bev plus CBDCA/nab-PTX, a novel combination, might have efficacy with acceptable toxicities in chemotherapy-na ïve non-SQ NSCLC patients with MPE.Trial Registration University Hospital Medical Information Network in Japan (UMIN) Clinical Trials Registry (No. UMIN000013329) registered on 4th March 2014.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Anemia | Avastin | Bleeding | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Drugs & Pharmacology | Hematology | Investigational New Drugs | Japan Health | Lung Cancer | Non-Small Cell Lung Cancer | Study | Toxicology